Patents Assigned to TURNSTONE LIMITED PARTNERSHIP
  • Publication number: 20210187048
    Abstract: Embodiments of the invention include compositions and methods related to non-VSV rhabdoviruses and their use as anti-cancer therapeutics. Such rhabdoviruses possess tumor cell killing properties in vitro and in vivo.
    Type: Application
    Filed: December 7, 2020
    Publication date: June 24, 2021
    Applicant: TURNSTONE LIMITED PARTNERSHIP
    Inventors: David F. STOJDL, John BELL
  • Publication number: 20210128706
    Abstract: There is described a kit for use in inducing an immune response in a mammal, the kit includes: a first virus that expresses MAGEA3, Human Papilloma Virus E6/E7 fusion protein, human Six-Transmembrane Epithelial Antigen of the Prostate protein, or Cancer Testis Antigen 1, or a variant thereof as an antigenic protein and that is formulated to generate an immunity to the protein or variant thereof in the mammal. The kit also includes a Maraba MG1 virus encoding the same antigen, or a variant of the same antigen. The Maraba MG1 virus is formulated to induce the immune response in the mammal. The first virus is immunologically distinct from the Maraba MG1 virus.
    Type: Application
    Filed: September 9, 2020
    Publication date: May 6, 2021
    Applicant: TURNSTONE LIMITED PARTNERSHIP
    Inventors: David F. STOJDL, John Cameron BELL, Brian LICHTY, Jonathan POL
  • Patent number: 10925946
    Abstract: In one aspect, a method of treating cancer in a mammal is provided. The method comprises administering to the mammal an oncolytic vector that expresses a tumour antigen to which the mammal has a pre-existing immunity. In another aspect, a method of boosting immune response in a mammal having a pre-existing immunity to an antigen is provided comprising intravenous administration to the mammal of a B-cell infecting vector that expresses the antigen.
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: February 23, 2021
    Assignee: Turnstone Limited Partnership
    Inventors: Brian Lichty, Byram Bridle, Yonghong Wan, Jonathan Bramson
  • Publication number: 20200397892
    Abstract: Herein is described oncolytic viruses for use as immunologic adjuvants. There is provided a method of adjuvanting an immune response to an antigenic protein in a mammalian subject by administering the oncolytic virus and at least one antigenic peptide, with the latter not encoded by the former. Without the requirement for the virus to encode the antigenic protein, therapies may be readily personalized or formulated. The virus may be attenuated or inactivated. Prime:boost therapies for tumours are also provided, in which the prime comprises at least one antigenic protein, the boost comprises a virus and at least one antigenic protein, the at least one antigenic protein of the prime and the at least one antigenic protein of the boost are based on the same at least one tumour associated antigen, and the at least one antigenic protein of the boost is not encoded by the virus of the boost.
    Type: Application
    Filed: February 22, 2019
    Publication date: December 24, 2020
    Applicant: TURNSTONE LIMITED PARTNERSHIP
    Inventors: Marie-Claude BOURGEOIS-DAIGNEAULT, John BELL
  • Patent number: 10660947
    Abstract: There is described a kit for use in inducing an immune response in a mammal, the kit includes: a first virus that expresses MAGEA3, Human Papilloma Virus E6/E7 fusion protein, human Six-Transmembrane Epithelial Antigen of the Prostate protein, or Cancer Testis Antigen 1, or a variant thereof as an antigenic protein and that is formulated to generate an immunity to the protein or variant thereof in the mammal. The kit also includes a Maraba MG1 virus encoding the same antigen, or a variant of the same antigen. The Maraba MG1 virus is formulated to induce the immune response in the mammal. The first virus is immunologically distinct from the Maraba MG1 virus.
    Type: Grant
    Filed: January 16, 2019
    Date of Patent: May 26, 2020
    Assignee: TURNSTONE LIMITED PARTNERSHIP
    Inventors: David F. Stojdl, John Cameron Bell, Brian Lichty
  • Patent number: 10646557
    Abstract: There is described a kit for use in inducing an immune response in a mammal, the kit includes: a first virus that expresses MAGEA3, Human Papilloma Virus E6/E7 fusion protein, human Six-Transmembrane Epithelial Antigen of the Prostate protein, or Cancer Testis Antigen 1, or a variant thereof as an antigenic protein and that is formulated to generate an immunity to the protein or variant thereof in the mammal. The kit also includes a Maraba MG1 virus encoding the same antigen, or a variant of the same antigen. The Maraba MG1 virus is formulated to induce the immune response in the mammal. The first virus is immunologically distinct from the Maraba MG1 virus.
    Type: Grant
    Filed: January 16, 2019
    Date of Patent: May 12, 2020
    Assignee: TURNSTONE LIMITED PARTNERSHIP
    Inventors: David F. Stojdl, John Cameron Bell, Brian Lichty
  • Patent number: 10604741
    Abstract: Described herein is a method of enhancing virus replication in permissive cells that express a receptor to FGF2 protein. The method includes administering FGF2 protein or a functional variant thereof and the virus to the permissive cells. An oncolytic virus having a genome that includes an open reading frame that encodes FGF2 protein or a functional variant thereof is also described.
    Type: Grant
    Filed: March 13, 2018
    Date of Patent: March 31, 2020
    Assignee: TURNSTONE LIMITED PARTNERSHIP
    Inventors: Carolina Solange Ilkow, Fabrice Le Boeuf, John Cameron Bell, Jean-Simon Diallo, Rozanne Arulanandam
  • Patent number: 10603351
    Abstract: In one aspect, the invention provides methods for preferentially killing target proliferating cells in a host, such as cancer cells, by infecting host tissues with two or more strains of virus. The strains of virus may be selected to provide a synergistic and symbiotic effect, involving a contemporaneous lytic infection in the target proliferating cells. In selected embodiments, the viruses are selected so that expression of a first virulence factor in proliferating cells infected with the first virus increases the lytic effect of the second virus; and, expression of the second virulence factor in proliferating cells infected with the second virus increases the lytic effect of the first virus. The genomes of the first and second viruses may be selected so that they are incompatible for recombination between the viral genomes in cells of the host.
    Type: Grant
    Filed: August 20, 2009
    Date of Patent: March 31, 2020
    Assignee: TURNSTONE LIMITED PARTNERSHIP
    Inventors: John C. Bell, Fabrice Le Boeuf
  • Patent number: 10363293
    Abstract: There is described a kit for use in inducing an immune response in a mammal, the kit includes: a first virus that expresses MAGEA3, Human Papilloma Virus E6/E7 fusion protein, human Six-Transmembrane Epithelial Antigen of the Prostate protein, or Cancer Testis Antigen 1, or a variant thereof as an antigenic protein and that is formulated to generate an immunity to the protein or variant thereof in the mammal. The kit also includes a Maraba MG1 virus encoding the same antigen, or a variant of the same antigen. The Maraba MG1 virus is formulated to induce the immune response in the mammal. The first virus is immunologically distinct from the Maraba MG1 virus.
    Type: Grant
    Filed: February 20, 2014
    Date of Patent: July 30, 2019
    Assignee: Turnstone Limited Partnership
    Inventors: David F. Stojdl, John Cameron Bell, Brian Lichty, Jonathan Pol
  • Publication number: 20180369303
    Abstract: Embodiments of the invention include compositions and methods related to non-VSV rhabdoviruses and their use as anti-cancer therapeutics. Such rhabdoviruses possess tumor cell killing properties in vitro and in vivo.
    Type: Application
    Filed: August 10, 2018
    Publication date: December 27, 2018
    Applicant: TURNSTONE LIMITED PARTNERSHIP
    Inventors: David F. STOJDL, John BELL
  • Patent number: 10066214
    Abstract: Described herein is a method of enhancing virus replication in permissive cells that express a receptor to FGF2 protein. The method includes administering FGF2 protein or a functional variant thereof and the virus to the permissive cells. An oncolytic virus having a genome that includes an open reading frame that encodes FGF2 protein or a functional variant thereof is also described.
    Type: Grant
    Filed: June 16, 2014
    Date of Patent: September 4, 2018
    Assignee: Turnstone Limited Partnership
    Inventors: Carolina Solange Ilkow, Fabrice Le Boeuf, John Cameron Bell, Jean-Simon Diallo, Rozanne Arulanandam
  • Patent number: 9896664
    Abstract: Embodiments of the invention include compositions and methods related to Maraba virus and their use as anti-cancer therapeutics. Such rhabdoviruses possess tumor cell killing properties in vitro and in vivo.
    Type: Grant
    Filed: April 24, 2015
    Date of Patent: February 20, 2018
    Assignee: Turnstone Limited Partnership
    Inventors: John C. Bell, David F. Stojdl
  • Patent number: 9821054
    Abstract: A vaccination method is provided. The method comprises administering to a mammal a histone deacytelase inhibitor in conjunction with a vaccine that expresses an antigen to which the mammal has a pre-existing immunity.
    Type: Grant
    Filed: March 9, 2012
    Date of Patent: November 21, 2017
    Assignee: Turnstone Limited Partnership
    Inventors: Byram Bridle, Brian Lichty, Yonghong Wan, Jean-Simon Diallo, Chantal Lemay, John Bell
  • Patent number: 9707285
    Abstract: In one aspect, a method of treating cancer in a mammal is provided. The method comprises administering to the mammal an oncolytic vector that expresses a tumor antigen to which the mammal has a pre-existing immunity. In another aspect, a method of boosting immune response in a mammal having a pre-existing immunity to an antigen is provided comprising intravenous administration to the mammal of a B-cell infecting vector that expresses the antigen.
    Type: Grant
    Filed: March 16, 2010
    Date of Patent: July 18, 2017
    Assignee: Turnstone Limited Partnership
    Inventors: Brian Lichty, Byram Bridle, Yonghong Wan, Jonathan Bramson
  • Patent number: 9572883
    Abstract: Embodiments of the invention include compositions and methods related to non-VSV rhabdoviruses and their use as anti-cancer therapeutics. Such rhabdoviruses possess tumor cell killing properties in vitro and in vivo.
    Type: Grant
    Filed: July 8, 2013
    Date of Patent: February 21, 2017
    Assignee: TURNSTONE LIMITED PARTNERSHIP
    Inventors: David F. Stojdl, John Bell